Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Affiliations

• ¹ University Hospital Heidelberg, Heidelberg, Germany. lsellner.hd@gmail.com.
• ² Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany. lsellner.hd@gmail.com.
• ³ University of Dresden, Dresden, Germany.
• ⁴ EBMT Data Office, Leiden, The Netherlands.
• ⁵ University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
• ⁶ Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
• ⁷ University Hospital of Essen, Essen, Germany.
• ⁸ Ospedale Infantile Regina Margherita, Turin, Italy.
• ⁹ University Hospital of Basel, Basel, Switzerland.
• ¹⁰ University Hospital of Zurich, Zurich, Switzerland.
• ¹¹ Hematology and cell therapy department, Centre hospitalier Universitaire, Université de Tours, CIC Inserm 1415, Tours, France.
• ¹² Sez. Ematologia, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica Sacro Cuore, Rome, Italy.
• ¹³ University Hospital Eppendorf, Hamburg, Germany.
• ¹⁴ University Hospital Goettingen, Goettingen, Germany.
• ¹⁵ University Hospital Maastricht, Maastricht, The Netherlands.
• ¹⁶ University Hospital Brno, Brno, Czech Republic.
• ¹⁷ University Hospital of Angers, Angers, France.
• ¹⁸ Gustave Roussy Cancer Campus, Villejuif, France.
• ¹⁹ Charles University Hospital, Pilsen, Czech Republic.
• ²⁰ GKT School of Medicine, London, UK.
• ²¹ Divisione di Ematologia, AO SS Antonio e Biagio e Cesare Arrigo Alessandria, Alessandria, Italy.
• ²² Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland.
• ²³ Bristol Royal Hospital for Children, Bristol, UK.
• ²⁴ Univ. Lille, Inserm, CHU Lille, INSERM, Infinite, U1286F-59000, Lille, France.
• ²⁵ St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
• ²⁶ University Hospital Heidelberg, Heidelberg, Germany.